M. C. Avendaño López
464
REFERENCIAS
1.
Suzuki, S.; Li, X. K.; Enosawa, S.; Shinomiya, T. “A new immunosuppressant: FTY720, induces
bcl-‐2-‐associated apoptotic cell death in human lymphocytes”
Immunology
1996
,
89
, 518-‐
523.
2. a) Adachi, K.; Kohara, T.; Nakao, N.; Arita, M.; Chiba, K.; Mishina, T.; Sasaki, S.; Fujita, T.
“Design, synthesis and structure-‐activity relationships of 2-‐substituted 2-‐amino-‐1,3-‐
propanediols: Discovery of a novel immunosuppressant, FTY720”
Bioorg. Med. Chem. Lett
.
1995
,
5
, 853-‐856. b) Fujita, T.; Hirose, R.; Yoneta, M.; Sasaki, S.; Inoue, K.; Kiuchi, M.;
Hirase, S.; Chiba, K.; Sakamoto, H.; Arita, M. “Potent immunosuppressants, 2-‐alkyl-‐2-‐
aminopropane-‐1,3-‐diols”
J. Med. Chem
.
1996
,
39
, 4451-‐4459.
4.
Brinkmann, V. “Sphingosine 1-‐phosphate receptors in health and disease: mechanistic
insights from gene deletion studies and reverse pharmacology”
Pharmacol. Ther.
2007,
115, 84-‐105.
5. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.;
Proia, R. L.; Cyster, J. G. “Lymphocyte egress from thymus and peripheral lymphoid organs
is dependent on S1P receptor 1”
Nature
2004
,
427
, 355-‐360.
6. a) Albert, R.; Hinterding, K.; Brinkmann, V.; Guerini, D.; Müller-‐Hartwieg, C.; Knecht, H.;
Simeon, C.; Streiff, M.; Wagner, T.; Welzenbach, K.; Zecri, F.; Zollinger, M.; Cooke, N.;
Francotte, E. “Novel immunomodulator FTY720 is phosphorylated in rats and humans to
form a single stereoisomer. Identification: chemical proof, and biological characterization
of the biologically active species and its enantiomer”
J. Med. Chem.
2005
,
48
, 5373-‐5377. b)
Bandhuvula, P.; Tam, Y. Y.; Oskouian, B.; Saba, J. D. “The immune modulator FTY720
inhibits sphingosine-‐1-‐phosphate lyase activity”
J. Biol. Chem.
2005
,
280
, 33697-‐33700.
7. Seder, R. A.; Darrah, P. A.; Roederer, M. “T-‐cell quality in memory and protection:
implications for vaccine design”
Nat. Rev. Immunol.
2008
,
8
, 247-‐259.
8
. Pham, T. H.; Okada, T.; Matloubian, M.; Lo, C. G.; Cyster, J. G. “S1P1 receptor signaling
overrides retention mediated by Gai-‐coupled receptors to promote T cell egress”
Immunity
2008
,
28
,
122-‐133.
9. a)
Metzler, B.; Gfeller, P.; Wieczorek, G.; Li, J.; Nuesslein-‐Hildesheim, B.; Katopodis, A.;
Mueller, M.; Brinkmann, V. “Modulation of T cell homeostasis and alloreactivity under
continuous FTY720 exposure”
Int. Immunol.
2008
,
20
, 633-‐644. b) Pham, T. H.; Baluk, P.;
Xu, Y.; Grigorova, I.; Bankovich, A. J.; Pappu, R.; Coughlin, S. R.; McDonald, D. M.; Schewab,
S. R.; Cyster, J. C. “Lymphatic endothelial cell sphingosine kinase activity is required for
lymphocyte egress and lymphatic patterning”
J. Exp. Med
.
2010
,
207
, 17-‐27.
10. Kunzendorf, U.; Ziegler, E.; Kabelitz, D. “FTY720-‐the first compound of a new promising
class of immunosuppressive drugs”
Nephrol. Dial. Transplant
2004
,
19
, 1677-‐1681.
11. a) Matsuura, M.; Imayoshi, T.; Chiba, K.; Okumoto, T. “Effect of FTY720, a novel
immunosuppressant, on adjuvant-‐induced arthritis in rats”
Inflamm. Res.
2000
,
49
, 404-‐
410. b) Kitabayashi, H.; Isobe, M.; Watanabe, N.; Suzuki, J.; Yazaki, Y.; Sekiguchi, M.
“FTY720 prevents development of experimental autoimmune myocarditis through
reduction of circulating lymphocytes”
J. Cardiovasc. Pharmacol.
2000
,
35
, 410-‐416. c)
Kohno, T.; Tsuji, T.; Hirayama, K.; Watanabe, K.; Matsumoto, A.; Kohno, T.; Fujita, T. “A
novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice”
Biol.
Pharm. Bull.
2004
,
27
, 1392-‐1396. d) Mansoor, M.; Meléndez, A. J. “Recent trials for
FTY720 (fingolimod): a new generation of immunomodulators structurally similar to
sphingosine”
Rev. Recent Clin. Trial
s
2008
,
3
, 62-‐69.
12. a) Balatoni, B.; Storch, M. K.; Swoboda, E. M.; Schönborn, V.; Koziel, A.; Lambrou, Balatoni,
B.; Storch, M.K.; Swoboda, E.M.; Schonborn, V.; Koziel, A.; Lambrou, G.N.; Hiestand, P.C.;
Weissert, R.; Foster, C.A. “FTY720 sustains and restores neuronal function in the DA rat
model of MOG-‐induced experimental autoimmune encephalomyelitis”
Brain Res. Bull.
2007
,
74
, 307-‐316. b) Webb, M.; Tham, C. S.; Lin, F. F.; Lariosa-‐Willingham, K.Yu, N.; Hale,
J.; Mandala, S.; Chun, J.; Rao, T. S. “Sphingosine 1-‐phosphate receptor agonists attenuate
relapsing-‐remitting experimental autoimmune encephalitis in SJL mice”
J. Neuroimmunol.
2004
,
153
,108-‐121. c) Kataoka, H.; Sugahara, K.; Shimano, K.; Teshima, K.; Koyama, M.;
Fukunari, A.; Chiba, K. “FTY720: sphingosine 1-‐phosphate receptor modulator,
ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell
infiltration”
Cell Mol. Immunol.
2005
,
2
, 439-‐448.
13. a) Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.;
